A detailed history of Citigroup Inc transactions in Castle Biosciences Inc stock. As of the latest transaction made, Citigroup Inc holds 25,579 shares of CSTL stock, worth $735,396. This represents 0.0% of its overall portfolio holdings.

Number of Shares
25,579
Previous 68,234 62.51%
Holding current value
$735,396
Previous $1.49 Million 50.91%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

SELL
$17.4 - $31.47 $742,196 - $1.34 Million
-42,655 Reduced 62.51%
25,579 $729,000
Q2 2024

Aug 12, 2024

BUY
$18.84 - $24.94 $1.16 Million - $1.54 Million
61,580 Added 925.46%
68,234 $1.49 Million
Q1 2024

May 10, 2024

BUY
$18.06 - $25.3 $19,306 - $27,045
1,069 Added 19.14%
6,654 $147,000
Q4 2023

Feb 09, 2024

BUY
$12.19 - $22.43 $34,802 - $64,037
2,855 Added 104.58%
5,585 $120,000
Q3 2023

Nov 09, 2023

SELL
$13.28 - $20.3 $112,123 - $171,392
-8,443 Reduced 75.57%
2,730 $46,000
Q2 2023

Aug 10, 2023

BUY
$11.66 - $26.0 $98,258 - $219,102
8,427 Added 306.88%
11,173 $153,000
Q1 2023

May 11, 2023

SELL
$19.47 - $28.49 $14,135 - $20,683
-726 Reduced 20.91%
2,746 $62,000
Q4 2022

Feb 09, 2023

SELL
$18.08 - $30.0 $1.51 Million - $2.51 Million
-83,501 Reduced 96.01%
3,472 $81,000
Q3 2022

Nov 10, 2022

SELL
$22.51 - $34.32 $1.03 Million - $1.58 Million
-45,964 Reduced 34.58%
86,973 $2.27 Million
Q2 2022

Aug 10, 2022

BUY
$16.0 - $45.99 $1.99 Million - $5.72 Million
124,294 Added 1438.09%
132,937 $2.92 Million
Q1 2022

May 12, 2022

SELL
$33.17 - $46.98 $196,499 - $278,309
-5,924 Reduced 40.67%
8,643 $388,000
Q4 2021

Feb 10, 2022

SELL
$39.06 - $67.58 $41,442 - $71,702
-1,061 Reduced 6.79%
14,567 $624,000
Q3 2021

Nov 10, 2021

BUY
$60.13 - $77.6 $939,711 - $1.21 Million
15,628 New
15,628 $1.04 Million

Others Institutions Holding CSTL

About CASTLE BIOSCIENCES INC


  • Ticker CSTL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 26,297,000
  • Market Cap $756M
  • Description
  • Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. The company als...
More about CSTL
Track This Portfolio

Track Citigroup Inc Portfolio

Follow Citigroup Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

News

Stay updated on Citigroup Inc with notifications on news.